Loading
A phase 3 trial testing MRG003 in head and neck squamous cell carcinoma, now recruiting.
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN is a phase 3 interventional study registered as NCT05751512, led by Lepu Biopharma, and recruiting on the registry. Official title: A Randomised, Open-Label, Multicenter, Phase III Study to Evaluate MRG003 vs Cetuximab/Methotrexate as Second/Third Line of Treatment in Patient With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN). Planned enrolment is 180 participants (estimated). The study started in 2023-04-04 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.
Shares MRG003, Lepu Biopharma.
Shares MRG003, Lepu Biopharma.
Shares Lepu Biopharma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.